share_log

Maia Biotechnology Receives FDA Orphan Drug Designation For THIO For The Treatment Of Small-Cell Lung Cancer

Maia Biotechnology Receives FDA Orphan Drug Designation For THIO For The Treatment Of Small-Cell Lung Cancer

美亞生物科技獲 FDA 認定用於治療小細胞肺癌的 THIO 孤兒藥
Benzinga Real-time News ·  2022/08/02 08:05

$MAIA Biotechnology(MAIA.US)$ ("MAIA", the "Company"), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to THIO, a telomere-targeting agent currently in development to evaluate its activity in multiple cancer indications, for the treatment of small-cell lung cancer (SCLC). 

$ 馬亞生物技術（美國）$ (以下簡稱「MAIA」) 今天宣布，美國食品藥物管理局 (FDA) 已向目前正在開發中的一流腫瘤藥物標靶劑 THIO 授予孤兒藥物名稱 (ODD)，以評估其在多種癌症適應症中的活性，用於治療小細胞肺癌 (SCLC)。

This is the second orphan drug designation granted to THIO, following receipt of orphan designation for hepatocellular carcinoma (HCC).

這是在收到肝細胞癌（HCC）的孤兒指定後，被授予 THIO 的第二種孤兒藥物。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論